ARMR Sciences Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.

ARMR Sciences Inc., a biodefense technology company, announced the completion of a private placement financing with strategic and institutional investors. Joseph Gunnar & Co., LLC acted as the placement agent for the offering. The funds will support the continued development and clinical progression of the company's fentanyl vaccine, which is designed to prevent fatal overdoses and address threats from synthetic substances like fentanyl.

Backed by early-stage research funding from the U.S. Department of Defense, ARMR Sciences is developing the first long-acting, preventive immunotherapy to stop synthetic drug overdose before it begins. Fentanyl is currently the leading cause of death for U.S. adults aged 18 to 45. The company's vaccine represents a critical shift in national strategy from reacting to overdoses to preventing them at the source.

Qualified prospective investors who meet the qualifications of an accredited investor can invest $5,000 in this offering and become shareholders. For more information, visit https://armrsciences.com/.

The announcement highlights the potential impact of this vaccine in combating the opioid crisis. With the backing of the U.S. Department of Defense, ARMR Sciences is positioned to advance its clinical trials and bring a novel solution to market. This development is significant as it aims to prevent overdoses, which have become a major public health and national security concern.

ARMR Sciences Inc. is America's biodefense technology company, developing next-generation countermeasures against synthetic drug threats. Through its foundational license from the U.S. Department of Defense, the company is pioneering preventive immunotherapy for synthetic drug overdose. The private placement led by Joseph Gunnar & Co. underscores investor confidence in the company's mission and technology.

For more details on the announcement, visit https://ibn.fm/t39w2.